BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8195034)

  • 1. The effect of low pH and hypoxia on the cytotoxic effects of SR4233 and mitomycin C in vitro.
    Skarsgard LD; Vinczan A; Skwarchuk MW; Chaplin DJ
    Int J Radiat Oncol Biol Phys; 1994 May; 29(2):363-7. PubMed ID: 8195034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation.
    Keohane A; Godden J; Stratford IJ; Adams GE
    Br J Cancer; 1990 May; 61(5):722-6. PubMed ID: 2110815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of pH on the aerobic and hypoxic cytotoxicity of SR4233 in HT-29 cells.
    Skarsgard LD; Skwarchuk MW; Vinczan A; Chaplin DJ
    Br J Cancer; 1993 Oct; 68(4):681-3. PubMed ID: 8398693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay.
    Stratford IJ; Stephens MA
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):973-6. PubMed ID: 2495261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA damaging effects and voltammetric studies on the hypoxic cell toxin 3-amino-1,2,4-benzotriazine-1,4-dioxide, SR4233, as a function of pH.
    Tocher JH; Virk NS; Edwards DI
    Biochem Pharmacol; 1990 Sep; 40(6):1405-10. PubMed ID: 2144963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin.
    Koch CJ
    Cancer Res; 1993 Sep; 53(17):3992-7. PubMed ID: 8358728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia.
    Blumenthal RD; Taylor A; Osorio L; Ochakovskaya R; Raleigh JA; Papadopoulou M; Bloomer WD; Goldenberg DM
    Int J Cancer; 2001 Nov; 94(4):564-71. PubMed ID: 11745445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of micronucleus induction in SCCVII cells treated with bioreductive agents, WIN 59075 (SR 4233) and mitomycin C, under aerobic and hypoxic conditions.
    Shibata T; Shibamoto Y; Sasai K; Oya N; Takagi T; Murata R; Abe M
    Mutat Res; 1995 Apr; 342(3-4):171-7. PubMed ID: 7715618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.
    Saunders MP; Patterson AV; Chinje EC; Harris AL; Stratford IJ
    Br J Cancer; 2000 Feb; 82(3):651-6. PubMed ID: 10682679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
    Patterson AV; Saunders MP; Chinje EC; Talbot DC; Harris AL; Strafford IJ
    Br J Cancer; 1997; 76(10):1338-47. PubMed ID: 9374381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.
    Shibata T; Shibamoto Y; Sasai K; Oya N; Murata R; Takagi T; Hiraoka M; Takahashi M; Abe M
    Br J Cancer Suppl; 1996 Jul; 27():S61-4. PubMed ID: 8763848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioreductive drugs and the selective induction of tumour hypoxia.
    Bremner JC; Stratford IJ; Bowler J; Adams GE
    Br J Cancer; 1990 May; 61(5):717-21. PubMed ID: 2110814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model.
    Hicks KO; Fleming Y; Siim BG; Koch CJ; Wilson WR
    Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):641-9. PubMed ID: 9806526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines.
    Zhang M; Stevens G
    Melanoma Res; 1998 Dec; 8(6):510-5. PubMed ID: 9918413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
    Monge A; Palop JA; López de Ceráin A; Senador V; Martínez-Crespo FJ; Sainz Y; Narro S; García E; de Miguel C; González M
    J Med Chem; 1995 May; 38(10):1786-92. PubMed ID: 7752202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells.
    Fracasso PM; Sartorelli AC
    Cancer Res; 1986 Aug; 46(8):3939-44. PubMed ID: 3089583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of hypoxia on the cytotoxicity of concomitant KW-2149 and ionizing irradiation in Chinese hamster fibroblasts.
    Egelmeers A; Dirix LY; Lyczek J; De Bruijn EA; Van Oosterom AT; Scalliet P
    Anticancer Drugs; 1996 Jul; 7(5):586-90. PubMed ID: 8862727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under acidic conditions.
    Begleiter A; Leith MK
    Mol Pharmacol; 1993 Jul; 44(1):210-5. PubMed ID: 8341273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Over-expression of Bcl-2 protects against apoptosis induced by the bioreductive cytotoxic drug SR4233 (Tirapazamine).
    Gilbert MS; Rupnow BA; Ramirez DA; Trisler KD; Knox SJ
    Cell Death Differ; 1996 Apr; 3(2):215-22. PubMed ID: 17180085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake.
    Skarsgard LD; Skwarchuk MW; Vinczan A; Kristl J; Chaplin DJ
    Anticancer Res; 1995; 15(1):219-23. PubMed ID: 7733636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.